We’re working to bring a first-in-class Autism treatment to market. We believe this treatment has the potential to affect both core and non-core symptoms in children with Autism. Take a closer look at what we’ve discovered, and learn more about our novel approach.
5.4 million children in the U.S., aged 4-17 years old (or 3-9% of school aged population) have been diagnosed with Attention-Deficit Hyperactivity Disorder (ADHD)—characterized by inattention, hyperactivity and impulsivity.
Our drug candidate, CM-1212, seeks to treat alcohol and drug addiction. Individuals addicted to drugs and alcohol lack the ability to properly digest and absorb essential nutrients. Emerging research indicates a role for amino acids in the persistence of addictive behaviors.
The current treatment for schizophrenia, antipsychotics, can lead to numerous side effects, including drowsiness, dizziness, and rapid heartbeat.
We are developing an enzyme replacement therapy, CM-182, that may be helpful in the treatment of schizophrenia. Animal model studies of CM-182 have shown effectiveness in treating the positive symptoms of schizophrenia without sedation.
Curemark has built a broad pipeline of drug products that addresses an array of disorders.
The company’s lead asset, CM-AT, is an orally-delivered, BLA-ready treatment for Autism Spectrum Disorder (ASD). CM-AT is designed to treat the maladaptive behaviors of irritability, agitation, hyperactivity, non-compliance and inappropriate speech in children with Autism as young as age 3. The product is clinically validated and successfully completed 2 large, placebo controlled, randomized phase III trials.
Beyond ASD, Curemark has a diverse portfolio of additional clinical stage assets addressing ADHD, and Schizophrenia and Parkinson’s Disease. Click on the links above to read more about each of the assets in our pipeline. The video below offers an overview explaining what clinical trials are and how they are conducted.